Amarin Corp Plcuk (AMRN) Cash & Current Investments (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Cash & Current Investments of $177.0 million for Q1 2026, up 8.88% YoY from $162.6 million in Q1 2025, and down 41.5% sequentially from $302.6 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash & Current Investments (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Cash & Current Investments across 17 years of filings, most recently posting $177.0 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 8.88% year-over-year to $177.0 million; the TTM figure through Mar 2026 stood at $177.0 million (up 8.88% YoY), while the FY2025 annual figure was $302.6 million, up 74.42% from the prior year.
- Cash & Current Investments retreated to $177.0 million in Q1 2026, from $302.6 million in the prior quarter.
- Over the last five years, Cash & Current Investments for AMRN reached as high as $362.6 million in Q1 2022 and fell as low as $50.4 million in Q3 2023.
- The 5-year median for Cash & Current Investments is $173.5 million (2024), against an average of $198.7 million.
- Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 85.99% — and 2024, when it jumped 506.86%.
- A 5-year view of Cash & Current Investments shows it stood at $92.2 million in 2022, then soared by 32.22% to $121.9 million in 2023, then soared by 42.28% to $173.5 million in 2024, then soared by 74.42% to $302.6 million in 2025, then slumped by 41.5% to $177.0 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $177.0 million, $302.6 million, and $164.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.94 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 177.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 177.00 Mn |
| Dec 31, 2025 | 302.59 Mn |
| Sep 30, 2025 | 164.10 Mn |
| Jun 30, 2025 | 298.70 Mn |
| Mar 31, 2025 | 162.56 Mn |
| Dec 31, 2024 | 173.48 Mn |
| Sep 30, 2024 | 305.69 Mn |
| Jun 30, 2024 | 306.60 Mn |
| Mar 31, 2024 | 94.76 Mn |
| Dec 31, 2023 | 121.93 Mn |
| Sep 30, 2023 | 50.37 Mn |
| Jun 30, 2023 | 80.42 Mn |
| Mar 31, 2023 | 304.37 Mn |
| Dec 31, 2022 | 92.22 Mn |
| Sep 30, 2022 | 67.12 Mn |
| Jun 30, 2022 | 313.23 Mn |
| Mar 31, 2022 | 362.61 Mn |
| Dec 31, 2021 | 454.13 Mn |
| Sep 30, 2021 | 479.20 Mn |
| Jun 30, 2021 | 185.83 Mn |